The effects of N-glycosylation on the glucuronidation of zidovudine and morphine by UGT2B7 expressed in HEK293 cells

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 4, 2012, Pages 388-397

  Nagaoka, Kenjiro ^a   Hanioka, Nobumitsu ^a   Ikushiro, Shinichi ^b   Yamano, Shigeru ^c   Narimatsu, Shizuo ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

Morphine; Mutant; N glycosylation; UDPGA; UGT2B7; Zidovudine

Indexed keywords

ASPARAGINE; GLUCURONOSYLTRANSFERASE 2B7; GLUTAMINE; MORPHINE; N ACETYL BETA GLUCOSAMINIDASE; URIDINE DIPHOSPHATE GALACTOSE; ZIDOVUDINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CELL LYSATE; CELL STRAIN HEK293; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SUBSTRATE; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PROTEIN EXPRESSION; RESIDUE ANALYSIS; WILD TYPE;

EID: 84865360600     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-135     Document Type: Article

References (30)

1. Meech, R. and Mackenzie, P. I.: Structure and function of uridine diphosphate glucuronosyltransferases. Clin. Exp. Pharmacol. Physiol., 24: 907-915 (1997).
2. Ritter, J. K.: Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem. Biol. Interact., 129: 171-193 (2000).
3. Burchell, B.: Substrate specificity and properties of uridine diphosphate glucuronyltransferase purified to apparent homogeneity from phenobarbital-treated rat liver. Biochem. J., 173: 749-757 (1978).
4. Mackenzie, P. I., Owens, I. S., Burchell, B., Bock, K. W., Bairoch, A., Bélanger, A., Fournel-Gigleux, S., Green, M., Hum, D. W., Iyanagi, T., Lancet, D., Louisot, P., Magdalou, J., Chowdhury, J. R., Ritter, J. K., Schachter, H., Tephly, T. R., Tipton, K. F. and Nebert, D. W.: The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics, 7: 255-269 (1997).
5. Kiang, T. K., Ensom, M. H. and Chang, T. K.: UDPglucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther., 106: 97-132 (2005).
6. Court, M. H., Hazarika, S., Krishnaswamy, S., Finel, M. and Williams, J. A.: Novel polymorphic human UDP-glucuronosyltransferase (UGT. 2A3: Cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction. Mol. Pharmacol., 74: 744-754 (2008).
7. Miners, J. O. and Mackenzie, P. I.: Drug glucuronidation in humans. Pharmacol. Ther., 51: 347-369 (1991).
8. Radominska-Pandya, A., Ouzzine, M., Fournel-Gigleux, S. and Magdalou, J.: Structure of UDP-glucuronosyltransferases in membranes. Methods Enzymol., 400: 116-147 (2005).
9. Shepherd, S. R., Baird, S. J., Hallinan, T. and Burchell, B.: An investigation of the transverse topology of bilirubin UDPglucuronosyltransferase in rat hepatic endoplasmic reticulum. Biochem. J., 259: 617-620 (1989).
10. Meech, R. and Mackenzie, P. I.: Determinants of UDP glucuronosyltransferase membrane association and residency in the endoplasmic reticulum. Arch. Biochem. Biophys., 356: 77-85 (1998).
11. Basu, N. K., Kole, L., Basu, M., Chakraborty, K., Mitra, P. S. and Owens, I. S.: The major chemical-detoxifying system of UDPglucuronosyltransferases requires regulated phosphorylation supported by protein kinase C. J. Biol. Chem., 283: 23048-23061 (2008).
12. Mitra, P. S., Basu, N. K., Basu, M., Chakraborty, S., Saha, T. and Owens, I. S.: Regulated phosphorylation of a major UDPglucuronosyltransferase isozyme by tyrosine kinases dictates endogenous substrate selection for detoxification. J. Biol. Chem., 286: 1639-1648 (2011).
13. Barbier, O., Girard, C., Breton, R., Bélanger, A. and Hum, D. W.: N-glycosylation and residue 96 are involved in the functional properties of UDP-glucuronosyltransferase enzymes. Biochemistry, 39: 11540-11552 (2000).
14. Nakajima, M., Koga, T., Sakai, H., Yamanaka, H., Fujiwara, R. and Yokoi, T.: N-Glycosylation plays a role in protein folding of human UGT1A9. Biochem. Pharmacol., 79: 1165-1172 (2010).
15. Dong, M., Owens, I. S. and Sheen, Y. Y.: Cloning and expression of human liver UDP-glucuronosyltransferase cDNA, UDPGTh2. Arch. Pharm. Res., 20: 459-464 (1997).
16. Bañó-Polo, M., Baldin, F., Tamborero, S., Marti-Renom, M. A. and Mingarro, I.: N-glycosylation efficiency is determined by the distance to the C-terminus and the amino acid preceding an Asn-Ser-Thr sequon. Protein Sci., 20: 179-186 (2011).
17. Mellquist, J. L., Kasturi, L., Spitalnik, S. L. and Shakin-Eshleman, S. H.: The amino acid following an Asn-X-Ser/Thr sequon is an important determinant of N-linked core glycosylation efficiency. Biochemistry, 37: 6833-6837 (1998).
18. Gavel, Y. and von Heijne, G.: Sequence differences between glycosylated and non-glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein engineering. Protein Eng., 3: 433-442 (1990).
19. Wicker-Planquart, C., Canaan, S., Rivière, M. and Dupuis, L.: Site-directed removal of N-glycosylation sites in human gastric lipase. Eur. J. Biochem., 262: 644-651 (1999).
20. Shipley, J. M., Grubb, J. H. and Sly, W. S.: The role of glycosylation and phosphorylation in the expression of active human beta-glucuronidase. J. Biol. Chem., 268: 12193-12198 (1993).
21. Skropeta, D.: The effect of individual N-glycans on enzyme activity. Bioorg. Med. Chem., 17: 2645-2653 (2009).
22. Ouzzine, M., Barré, L., Netter, P., Magdalou, J. and Fournel-Gigleux, S.: Role of the carboxyl terminal stop transfer sequence of UGT1A6 membrane protein in ER targeting and translocation of upstream lumenal domain. FEBS Lett., 580: 1953-1958 (2006).
23. Mackenzie, P. I.: The effect of N-linked glycosylation on the substrate preferences of UDP glucuronosyltransferases. Biochem. Biophys. Res. Commun., 166: 1293-1299 (1990).
24. Ikushiro, S., Emi, Y., Kato, Y., Yamada, S. and Sakaki, T.: Monospecific antipeptide antibodies against human hepatic UDPglucuronosyltransferase 1A subfamily (UGT1A. isoforms. Drug Metab. Pharmacokinet., 21: 70-74 (2006).
25. Laemmli, U. K.: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227: 680-685 (1970).
26. Towbin, H., Staehelin, T. and Gordon, J.: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76: 4350-4354 (1979).
27. Court, M. H., Krishnaswamy, S., Hao, Q., Duan, S. X., Patten, C. J., von Moltke, L. L. and Greenblatt, D. J.: Evaluation of 3$-azido-3$-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7. in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab. Dispos., 31: 1125-1133 (2003).
28. Nakagawa, N., Katoh, M., Yoshioka, Y., Nakajima, M. and Yokoi, T.: Inhibitory effects of Kampo medicine on human UGT2B7 activity. Drug Metab. Pharmacokinet., 24: 490-499 (2009).
29. Hara, Y., Nakajima, M., Miyamoto, K. and Yokoi, T.: Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine. Drug Metab. Pharmacokinet., 22: 103-112 (2007).
30. Uchaipichat, V., Mackenzie, P. I., Guo, X.-H., Gardner-Stephen, D., Galetin, A., Houston, J. B. and Miners, J. O.: Human UDPglucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab. Dispos., 32: 413-423 (2004).